Current Research and Treatments Using Psychedelic Assisted Therapy

This presentation aims to provide a deeper understanding of the therapeutic work with MDMA and psilocybin for post-traumatic stress disorder (PTSD) and depression. Both substances have shown promising results in alleviating symptoms and providing long-lasting benefits for individuals suffering from these mental health conditions.

The first part of the presentation will focus on MDMA-assisted therapy for PTSD. Clinical studies show significant reductions in PTSD symptoms. The three-phase therapy, consisting of preparation, MDMA-assisted session, and integration, allows patients to explore and process their trauma in a controlled setting.

The second part of the presentation will explore psilocybin-assisted therapy for depression. Psilocybin, a naturally occurring psychedelic compound, induces altered states of consciousness and facilitates profound introspection. In a supportive environment, patients are able to explore their thoughts, emotions, and beliefs, leading to a shift in perspective and a deeper understanding of their depression. Clinical trials have shown significant reductions in depressive symptoms, even in treatment-resistant cases.